Management of Wolff-Parkinson-White Syndrome with Atrial Fibrillation

Introduction to Risk Factors

The combination of Wolff-Parkinson-White (WPW) syndrome and atrial fibrillation represents a potentially fatal condition, with a sudden death risk of 0.15-0.39% over 3-22 years of follow-up, increasing to 2.2% in symptomatic patients 1, 2.

The European Heart Journal recommends that patients with WPW syndrome and atrial fibrillation should avoid tranilcipromina, as it can precipitate hypertensive crises and tachyarrhythmias, which can degenerate into fatal ventricular fibrillation 1, 2.
The European Society of Cardiology notes that the use of tranilcipromina in patients with WPW syndrome and atrial fibrillation can increase the risk of sudden cardiac death through multiple mechanisms, including sympathetic effects, hypertensive crises, and QT interval prolongation 1, 2, 3, 4.

Patients with WPW syndrome and atrial fibrillation are at increased risk of sudden cardiac death, particularly if they have a short RR interval (<250 ms) during atrial fibrillation, and the use of tranilcipromina can exacerbate this condition 1, 2.

The American College of Cardiology recommends catheter ablation of the accessory pathway as the first-line treatment for symptomatic patients with WPW syndrome and atrial fibrillation, with a success rate >95% and a complication rate <1-2% in experienced centers 6, 1, 2.
The European Heart Journal suggests that after successful ablation, the risk of sudden cardiac death is eliminated, and the use of previously contraindicated medications can be reconsidered 1, 2.
The American Heart Association recommends that patients with WPW syndrome and atrial fibrillation should avoid certain medications, including beta-blockers, non-dihydropyridine calcium channel blockers, digoxin, and amiodarone, as they can accelerate conduction through the accessory pathway and precipitate ventricular fibrillation 3, 5, 8.

The European Society of Cardiology recommends considering selective serotonin reuptake inhibitors (SSRIs) as a safer alternative for depression in patients with WPW syndrome and atrial fibrillation, as they do not have significant sympathomimetic effects 5, 3.
The American Psychiatric Association suggests avoiding all monoamine oxidase inhibitors (MAOIs), including tranilcipromina, in this population, and consulting psychiatry and cardiology to develop an integrated treatment plan that prioritizes cardiovascular safety 5, 8.